glp-1 joint pain Inhibitor Reduces Knee Osteoarthritis UC Davis Health examines systemic

I focus on food (berries, greens, omega-3s), but Ive also taken a blend that includes grape seed + cherry for months

Results The patient was given Semax from August 2022 until August 2023

& Burch, A

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have gained considerable attention in recent years as promising therapeutic agents for MASLD, particularly owing to their well-established efficacy in treating type 2 diabetes mellitus (T2DM) and obesity, conditions closely implicated to MASLD pathogenesis (2, 5)

Semaglutide (Wegovy) was approved in 2021 and tirzepatide (Zepbound) in 2023

doi: 10.1016/j.clnu.2024.10.028